Heart failure & cardiomyopathiesDiagnostic or prognostic study
Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy
- Prognostic cohort study
- international
- multicentre
- blinded core laboratory
Authors' conclusion
In this multicenter cohort study among patients with ATTR-CM, a validated, risk-based conceptual framework of echocardiographic parameters to quantify TR improved prediction of mortality and HFH over standard classification of TR severity, better reflecting restrictive low-flow pathophysiology and supporting disease-specific TR grading in ATTR-CM.
Study context
- Population
- Patients with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM), 8 tertiary centres in Austria, Italy, Germany and the Netherlands, 2016–2026
- Participants
- 1,124 patients
- Comparison
- Derivation vs Validation
- Derivationn = 745
- Validationn = 379
- Outcome
- All-cause mortality
Performance
As reported in the abstract
Hazard ratio
1.41
95% CI 1.23–1.62
Disease-specific quantitative TR risk thresholds vs guideline and TVARC TR grading
HR 1.41 (95% CI 1.23–1.62)
- Deaths over median 25.2 months follow-up
- 324 (28.8%)
Secondary outcomes
Heart failure hospitalization (HFH)
| Comparison | HR (95% CI) | |
|---|---|---|
| Framework | 1.31 (1.12–1.54) | |
| 0.512Hazard ratio (log scale) |
- HFH — Patients with HFH
- 251 (22.3%)
Original publication
Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy. JAMA Cardiol. Published 31 August 2026. doi:10.1001/jamacardio.2026.3803
Summarised from the published abstract; every number is checked against it